Document Detail

A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure.
MedLine Citation:
PMID:  19841485     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: To assess the influence of beta2-receptor suppression on top of selective beta1-receptor blockade on the occurrence of vascular events and on all-cause mortality in patients with acute coronary syndrome (ACS) or heart failure (HF ). METHODS: Systematic review of studies published since 1980. Randomised controlled trials directly comparing beta1 blockers with beta1+2 blockers, or comparing the two beta blockers with placebo, were included. Studies had a minimum treatment period of three months and total mortality or vascular events as their primary or secondary outcome. RESULTS: Of the included studies, five directly compared beta blockers (3733 patients) and 28 compared beta blockers with placebo (30,889 patients). These latter studies were heterogeneous in study population, dose and type of beta blockers. In ACS, the only study directly comparing different beta blockers was underpowered to detect a difference on mortality, while in HF beta1+2 blockers significantly decreased mortality compared with b1 blockers (RR 0.86, 95% confidence interval 0.78 to 0.94). In ACS, beta1 blockers in placebo-controlled trials non-significantly reduced total mortality (RR 0.82, 0.67 to 1.01) or vascular events (RR 0.68, 0.42 to 1.11), while beta1+2 blockers were associated with a significant decrease in total mortality (RR 0.73, 0.64 to 0.82), and vascular events (RR 0.71, 0.59 to 0.84). In HF, beta1 and beta1+2 blockers reduced total mortality, while only beta1+2 blockers decreased vascular events (RR 0.80, 0.64 to 1.00). CONCLUSIONS: Additional beta2-receptor blockade may be more effective than beta1-receptor blockade alone in preventing total mortality and vascular events in patients with ACS or, to a lesser extent, HF . However, only a few studies directly compared beta blockers, and indirect comparisons were subject to heterogeneity, which weakens firm conclusions.
O R de Peuter; F Lussana; R J G Peters; H R B??ller; P W Kamphuisen
Related Documents :
16789795 - Zofenopril plus hydrochlorothiazide: combination therapy for the treatment of mild to m...
19710245 - Management of scorpion sting: prazosin or dobutamine.
18307835 - Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan ...
11127445 - Outcome of patients with congestive heart failure treated with standard versus high dos...
1992185 - Creutzfeldt-jakob disease in pituitary growth hormone recipients in the united states.
7613795 - Outcome of endoscopic bladder transection.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The Netherlands journal of medicine     Volume:  67     ISSN:  1872-9061     ISO Abbreviation:  Neth J Med     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-10-20     Completed Date:  2010-01-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0356133     Medline TA:  Neth J Med     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  284-94     Citation Subset:  IM    
Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / drug therapy*,  mortality
Adrenergic beta-Antagonists / therapeutic use*
Heart Failure / drug therapy*,  mortality
Reg. No./Substance:
0/Adrenergic beta-Antagonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Rhabdomyolysis: a review of the literature.
Next Document:  Heart failure as presenting manifestation of cardiac involvement in systemic lupus erythematosus.